Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis

Roberto Testa, Nadia Campo, Sergio Caglieris, Domenico Risso, Silvano Alvarez, Laura Arzani, Edoardo Giannini, Pasquale Bruno Lantieri, Guido Celle

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background/Aims: The aim of this study was to evaluate the relationship between plasma elimination of lidocaine and monoethylglycinexylidide (MEGX) formation, which is considered to be a quantitative liver function test. Methodology: The study included ten healthy subjects and 54 patients: 27 with chronic hepatitis and 27 with cirrhosis. Lidocaine and MEGX were measured at 0, 2, 5, 10, 15, 30 min and then every 30 min for 180 min using the TDX system. Results: In cirrhotic patients, the lidocaine half-life of the slow decline phase of the plasma disappearance curve (β-HL) and the lidocailze half-life of hepatic elimination from the second compartment (K20-HL) proved to be significantly abnormal, as did all parameters of MEGX formation. In chronic hepatitis, both the lidocaine kinetics and the MEGX formation parameters were within the normal range. In chronic hepatitis patients, MEGX formation (AUC 0-180) was significantly correlated to K20-HL (r(s) = -0.633, p <0.001) and to the rapid decline phase of the plasma disappearance curve (a-HL, r(s) = -0.483, p <0.05). In cirrhotic patients, MEGX was significantly correlated to K20-HL (r(s) = -0.423, p <0.05) and to β-HL (r(s) = -0.500, p <0.01). Conclusions: These results show that in chronic active hepatitis, MEGX formation from lidocaine is maintained as a metabolic process, whereas it is altered in cirrhotic patients. The interrelationship between lidocaine elimination and MEGX formation were somewhat different in the two liver diseases.

Original languageEnglish
Pages (from-to)154-159
Number of pages6
JournalHepato-Gastroenterology
Volume45
Issue number19
Publication statusPublished - 1998

Fingerprint

monoethylglycinexylidide
Chronic Hepatitis
Lidocaine
Fibrosis
Half-Life
Liver Function Tests
Area Under Curve
Liver Diseases
Healthy Volunteers
Reference Values

Keywords

  • Chronic hepatitis
  • Cirrhosis
  • Lidocaine
  • Monoethylglycinexylidide

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Testa, R., Campo, N., Caglieris, S., Risso, D., Alvarez, S., Arzani, L., ... Celle, G. (1998). Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis. Hepato-Gastroenterology, 45(19), 154-159.

Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis. / Testa, Roberto; Campo, Nadia; Caglieris, Sergio; Risso, Domenico; Alvarez, Silvano; Arzani, Laura; Giannini, Edoardo; Lantieri, Pasquale Bruno; Celle, Guido.

In: Hepato-Gastroenterology, Vol. 45, No. 19, 1998, p. 154-159.

Research output: Contribution to journalArticle

Testa, R, Campo, N, Caglieris, S, Risso, D, Alvarez, S, Arzani, L, Giannini, E, Lantieri, PB & Celle, G 1998, 'Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis', Hepato-Gastroenterology, vol. 45, no. 19, pp. 154-159.
Testa, Roberto ; Campo, Nadia ; Caglieris, Sergio ; Risso, Domenico ; Alvarez, Silvano ; Arzani, Laura ; Giannini, Edoardo ; Lantieri, Pasquale Bruno ; Celle, Guido. / Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis. In: Hepato-Gastroenterology. 1998 ; Vol. 45, No. 19. pp. 154-159.
@article{b315f256ef8c4640a0ee5ea0aeb01e84,
title = "Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis",
abstract = "Background/Aims: The aim of this study was to evaluate the relationship between plasma elimination of lidocaine and monoethylglycinexylidide (MEGX) formation, which is considered to be a quantitative liver function test. Methodology: The study included ten healthy subjects and 54 patients: 27 with chronic hepatitis and 27 with cirrhosis. Lidocaine and MEGX were measured at 0, 2, 5, 10, 15, 30 min and then every 30 min for 180 min using the TDX system. Results: In cirrhotic patients, the lidocaine half-life of the slow decline phase of the plasma disappearance curve (β-HL) and the lidocailze half-life of hepatic elimination from the second compartment (K20-HL) proved to be significantly abnormal, as did all parameters of MEGX formation. In chronic hepatitis, both the lidocaine kinetics and the MEGX formation parameters were within the normal range. In chronic hepatitis patients, MEGX formation (AUC 0-180) was significantly correlated to K20-HL (r(s) = -0.633, p <0.001) and to the rapid decline phase of the plasma disappearance curve (a-HL, r(s) = -0.483, p <0.05). In cirrhotic patients, MEGX was significantly correlated to K20-HL (r(s) = -0.423, p <0.05) and to β-HL (r(s) = -0.500, p <0.01). Conclusions: These results show that in chronic active hepatitis, MEGX formation from lidocaine is maintained as a metabolic process, whereas it is altered in cirrhotic patients. The interrelationship between lidocaine elimination and MEGX formation were somewhat different in the two liver diseases.",
keywords = "Chronic hepatitis, Cirrhosis, Lidocaine, Monoethylglycinexylidide",
author = "Roberto Testa and Nadia Campo and Sergio Caglieris and Domenico Risso and Silvano Alvarez and Laura Arzani and Edoardo Giannini and Lantieri, {Pasquale Bruno} and Guido Celle",
year = "1998",
language = "English",
volume = "45",
pages = "154--159",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "19",

}

TY - JOUR

T1 - Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis

AU - Testa, Roberto

AU - Campo, Nadia

AU - Caglieris, Sergio

AU - Risso, Domenico

AU - Alvarez, Silvano

AU - Arzani, Laura

AU - Giannini, Edoardo

AU - Lantieri, Pasquale Bruno

AU - Celle, Guido

PY - 1998

Y1 - 1998

N2 - Background/Aims: The aim of this study was to evaluate the relationship between plasma elimination of lidocaine and monoethylglycinexylidide (MEGX) formation, which is considered to be a quantitative liver function test. Methodology: The study included ten healthy subjects and 54 patients: 27 with chronic hepatitis and 27 with cirrhosis. Lidocaine and MEGX were measured at 0, 2, 5, 10, 15, 30 min and then every 30 min for 180 min using the TDX system. Results: In cirrhotic patients, the lidocaine half-life of the slow decline phase of the plasma disappearance curve (β-HL) and the lidocailze half-life of hepatic elimination from the second compartment (K20-HL) proved to be significantly abnormal, as did all parameters of MEGX formation. In chronic hepatitis, both the lidocaine kinetics and the MEGX formation parameters were within the normal range. In chronic hepatitis patients, MEGX formation (AUC 0-180) was significantly correlated to K20-HL (r(s) = -0.633, p <0.001) and to the rapid decline phase of the plasma disappearance curve (a-HL, r(s) = -0.483, p <0.05). In cirrhotic patients, MEGX was significantly correlated to K20-HL (r(s) = -0.423, p <0.05) and to β-HL (r(s) = -0.500, p <0.01). Conclusions: These results show that in chronic active hepatitis, MEGX formation from lidocaine is maintained as a metabolic process, whereas it is altered in cirrhotic patients. The interrelationship between lidocaine elimination and MEGX formation were somewhat different in the two liver diseases.

AB - Background/Aims: The aim of this study was to evaluate the relationship between plasma elimination of lidocaine and monoethylglycinexylidide (MEGX) formation, which is considered to be a quantitative liver function test. Methodology: The study included ten healthy subjects and 54 patients: 27 with chronic hepatitis and 27 with cirrhosis. Lidocaine and MEGX were measured at 0, 2, 5, 10, 15, 30 min and then every 30 min for 180 min using the TDX system. Results: In cirrhotic patients, the lidocaine half-life of the slow decline phase of the plasma disappearance curve (β-HL) and the lidocailze half-life of hepatic elimination from the second compartment (K20-HL) proved to be significantly abnormal, as did all parameters of MEGX formation. In chronic hepatitis, both the lidocaine kinetics and the MEGX formation parameters were within the normal range. In chronic hepatitis patients, MEGX formation (AUC 0-180) was significantly correlated to K20-HL (r(s) = -0.633, p <0.001) and to the rapid decline phase of the plasma disappearance curve (a-HL, r(s) = -0.483, p <0.05). In cirrhotic patients, MEGX was significantly correlated to K20-HL (r(s) = -0.423, p <0.05) and to β-HL (r(s) = -0.500, p <0.01). Conclusions: These results show that in chronic active hepatitis, MEGX formation from lidocaine is maintained as a metabolic process, whereas it is altered in cirrhotic patients. The interrelationship between lidocaine elimination and MEGX formation were somewhat different in the two liver diseases.

KW - Chronic hepatitis

KW - Cirrhosis

KW - Lidocaine

KW - Monoethylglycinexylidide

UR - http://www.scopus.com/inward/record.url?scp=0031914116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031914116&partnerID=8YFLogxK

M3 - Article

C2 - 9496506

AN - SCOPUS:0031914116

VL - 45

SP - 154

EP - 159

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 19

ER -